Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia

Leukemia Research

Volumn 33, Issue 10, 2009, Pages 1361-1366

  Hoshino, Koyu ^a   Quintás Cardama, Alfonso ^a   Radich, Jerald ^b   Dai, Hongyui ^c   Yang, Hui ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b USA   (United States)

^c ROSETTA INPHARMATICS   (United States)

Author keywords

Chronic myelogenous leukemia; DNA methylation; JUNB

Indexed keywords

BISULFITE; DNA; MESSENGER RNA; TRANSCRIPTION FACTOR JUNB;

ARTICLE; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA METHYLATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELL LINE, TUMOR; DNA METHYLATION; DNA PRIMERS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, TRANSGENIC; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-JUN; RESTRICTION MAPPING; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION, GENETIC;

EID: 67649383125     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.044     Document Type: Article

References (44)

1. Angel P., and Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochem Biophys Acta 1072 (1991) 129-157
2. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4 (2002) E131-E136
3. Deng T., and Karin M. Jun B differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes Dev 7 (1993) 479-490
4. Hsu J.C., Cressman D.E., and Taub R. Promoter-specific transactivation and inhibition mediated by JunB. Cancer Res 1993 53 (1993) 3789-3794
5. Schorpp-Kistner M., Wang Z.Q., Angel P., et al. JunB is essential for mammalian placentation. EMBO J 18 (1999) 934-948
6. INK4a expression. EMBO J 19 (2000) 2969-2979
7. Bakiri L., Lallemand D., Bossy-Wetzel E., et al. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 19 (2000) 2056-2068
8. Passegue E., Jochum W., Schorpp-Kistner M., et al. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage. Cell 104 (2001) 21-32
9. Lord K.A., Abdollahi A., Hoffman-Liebermann B., et al. Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation. Mol Cell Biol 13 2 (1993) 841-851
10. Mollinedo F., Vaquerizo M.J., and Naranjo J.R. Expression of c-jun, jun B and jun D proto-oncogenes in human peripheral-blood granulocytes. Biochem J 273 Pt 2 (1991) 477-479
11. Schreiber M., Kolbus A., Piu F., et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 13 (1999) 607-619
12. Chiu R., Angel P., and Karin M. Jun-B differs in its biological properties from and is a negative regulator of, c-Jun. Cell 59 (1989) 979-986
13. Schutte J., Viallet J., Nau M., et al. jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-Jun. Cell 59 (1989) 987-997
14. Melamed D., Resnitzky D., Haimov I., et al. Interleukin 6 induces DNA binding activity of AP1 in M1 myeloblastic cells but not in a growth resistant cell derivative. Cell Growth Differ 4 (1993) 689-697
15. Schlingensiepen K., Schlingensiepen R., Kunst M., et al. Opposite functions of jun-B and c-Jun in growth regulation and neuronal differentiation. Dev Genet 4 (1993) 305-312
16. Li B., Tournier C., Davis R.J., et al. Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. EMBO J 18 (1999) 420-432
17. Passegue E., Wagner E.F., and Weissman I.L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119 3 (2004) 431-443
18. Bruchova H., Borovanova T., Klamova H., et al. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk Lymphoma 43 6 (2002) 1289-1295
19. Yang M.Y., Liu T.C., Chang J.G., Lin P.M., and Lin S.F. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 101 (2003) 3205-3211
20. Xiong Z., and Laird P.W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25 (1997) 2532-2534
21. Shen L., Toyota M., Kondo Y., et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101 (2003) 4131-4136
22. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukaemia. Proc Natl Acad Sci USA 103 8 (2006) 2794-2799
23. Hughes T.R., Mao M., Jones A.R., et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol 19 (2001) 342-347
24. Van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
25. Issa J.P., Kantarjian H., Mohan A., et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood 93 (1999) 2075-2080
26. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 (2002) 415-428
27. Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91 (1994) 9700-9704
28. Dong S.M., Kim H.-S., Rha S.-H., and Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7 (2001) 1982-1996
29. Claus R., and Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 22 September (42) (2003) 6489-6496
30. Melki J.R., and Clark S.J. DNA methylation changes in leukaemia. Semin Cancer Biol 12 5 (2002) 347-357
31. Issa J.P., Baylin S.B., and Herman J.G. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 11 Suppl. 1 (1997) S7-S11
32. Baylin S.B., and Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16 (2000) 168-174
33. Robertson K.D. DNA methylation, methyltransferase, and cancer. Oncogene 20 (2001) 3139-3155
34. Nguyen T.T., Mohrbacher A.F., Tsai Y.C., et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood 95 (2000) 2990-2992
35. Asimakopoulos F.A., Shteper P.J., Krichevsky S., et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 94 (1999) 2452-2460
36. Roman-Gomez J., Castillejo J.A., Jimenez A., et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol 21 (2003) 1472-1479
37. Enokida H., Shiina H., Urakami S., et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American. Caucasian and Asian patients with prostate cancer. Int J Cancer 116 2 (2005) 174-181
38. Shen L., Ahuja N., Shen Y., et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 94 (2002) 755-761
39. Cameron E.E., Bachman K.E., and Myöhänen S. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21 (1999) 103-107
40. Lugo T.G., Pendergast A.M., Muller A.J., et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 4946 (1990) 1079-1082
41. Heisterkamp N., Jenster G., Hoeve J., et al. Acute leukaemia in bcr/abl transgenic mice. Nature 344 (1990) 251-253
42. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
43. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 December (23) (2006) 2408-2417
44. Cheshier S.H., Morrison S.J., Liao X., et al. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci USA 96 6 (1999) 3120-3125